文献速递眼底病与葡萄膜炎

OPT-302(一种VEGF-C/D抑制剂)治疗新生血管性年龄相关性黄斑变性的随机对照试验

A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2023-02-06

这项2b期随机双盲假注射对照试验纳入366例初治新生血管性年龄相关性黄斑变性患者,比较玻璃体腔注射0.5 mg或2.0 mg OPT-302联合0.5 mg雷珠单抗与假注射联合雷珠单抗的疗效与安全性。24周时,2.0 mg OPT-302组最佳矫正视力平均提升显著优于假注射组,0.5 mg组与假注射组无显著差异,各组不良事件相似。

要点

  • 2.0 mg OPT-302联合雷珠单抗组24周BCVA平均提升较假注射联合雷珠单抗组显著更优。
  • 0.5 mg OPT-302联合雷珠单抗组24周BCVA平均提升与假注射联合雷珠单抗组无显著差异。
  • 各组不良事件相似,2.0 mg组严重不良事件比例低于假注射组。

核心结论

  • 2.0 mg OPT-302联合雷珠单抗治疗较标准治疗观察到显著更优的视力提升,且安全性良好。

研究设计与样本

  • 剂量范围、2b期、随机、双盲、假注射对照试验,纳入初治新生血管性年龄相关性黄斑变性患者,来自欧洲、以色列和美国的109个中心。

主要发现

  • 2.0 mg OPT-302组24周BCVA平均提升+14.2±11.61个字母,显著优于假注射组的+10.8±11.52个字母(P=0.01)。
  • 0.5 mg OPT-302组24周BCVA平均提升+9.44±11.32个字母,与假注射组无显著差异(P=0.83)。
  • 与假注射组相比,2.0 mg OPT-302组的BCVA次要结局更有利,两个OPT-302剂量组的结构学结局均更有利。
  • 至少发生1次严重不良事件的参与者:0.5 mg组16例(13.3%)、2.0 mg组7例(5.6%)、假注射组10例(8.3%)。
  • 假注射组发生2例无关死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neovascular (wet) age-related macular degeneration (nAMD) is driven by VEGFs A, C, and D, which promote angiogenesis and vascular permeability. Intravitreal injections of anti-VEGF-A drugs are the standard of care, but these do not inhibit VEGF-C and D, which may explain why many patients fail to respond fully. This trial aimed to test the safety and efficacy of OPT-302, a biologic inhibitor of VEGF-C and D, in combination with the anti-VEGF-A inhibitor ranibizumab. DESIGN: Dose-ranging, phase 2b, randomized, double-masked, sham-controlled trial. PARTICIPANTS: Participants with treatment-naive nAMD were enrolled from 109 sites across Europe, Israel, and the United States. METHODS: Participants were randomized to 6, 4-weekly, intravitreal injections of 0.5 mg OPT-302, 2.0 mg OPT-302, or sham, plus intravitreal 0.5 mg ranibizumab. MAIN OUTCOME MEASURES: The primary outcome was mean change in ETDRS best-corrected visual acuity (BCVA) at 24 weeks. Secondary outcomes (comparing baseline with week 24) were the proportion of participants gaining or losing ≥ 15 ETDRS BCVA letters; area under the ETDRS BCVA over time curve; change in spectral-domain OCT (SD-OCT) central subfield thickness; and change in intraretinal fluid and subretinal fluid on SD-OCT. RESULTS: Of 366 participants recruited from December 1, 2017, to November 30, 2018, 122, 123, and 121 were randomized to 0.5 mg OPT-302, 2.0 mg OPT-302, and sham, respectively. Mean (± standard deviation) visual acuity gain in the 2.0 mg OPT-302 group was significantly superior to sham (+14.2 ± 11.61 vs. +10.8 ± 11.52 letters; P = 0.01). The 0.5 mg OPT-302 group was not significantly different than the sham group (+9.44 ± 11.32 letters; P = 0.83). Compared with sham, the secondary BCVA outcomes favored the 2.0 mg OPT-302 group, with structural outcomes favoring both OPT-302 dosage groups. Adverse events (AEs) were similar across groups, with 16 (13.3%), 7 (5.6%), and 10 (8.3%) participants in the lower-dose, higher-dose, and sham groups, respectively, developing at least 1 serious AE. Two unrelated deaths both occurred in the sham arm. CONCLUSIONS: Significantly superior vision gain was observed with OPT-302 2.0 mg combination therapy, versus standard of care, with favorable safety (ClinicalTrials.gov identifier: NCT03345082). FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Jackson TL, Slakter J, Buyse M, et al. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2023. PMID: 36754174. doi:10.1016/j.ophtha.2023.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。